$ANIX
Anixa Biosciences Inc

2024 Q1 Form 10-Q Financial Statement

#000149315224009683 Filed on March 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q1 2023 Q1
Revenue $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.260M $1.488M
YoY Change 51.88% -27.13%
% of Gross Profit
Research & Development $1.349M $1.068M
YoY Change 26.31% -41.89%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $3.609M $1.068M
YoY Change 237.92% -72.47%
Operating Profit -$3.609M -$2.556M
YoY Change 41.2% -34.12%
Interest Expense $319.0K $202.0K
YoY Change 57.92% 20100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$3.290M -$2.354M
YoY Change 39.76% -39.31%
Income Tax
% Of Pretax Income
Net Earnings -$3.255M -$2.322M
YoY Change 40.18% -39.36%
Net Earnings / Revenue
Basic Earnings Per Share $0.10 -$0.08
Diluted Earnings Per Share -$0.10 -$0.08
COMMON SHARES
Basic Shares Outstanding 31.70M shares 30.92M shares
Diluted Shares Outstanding 31.45K shares 30.92K shares

Balance Sheet

Concept 2024 Q1 2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $23.80M $27.70M
YoY Change -14.09% -19.77%
Cash & Equivalents $998.0K $9.790M
Short-Term Investments $22.80M $17.91M
Other Short-Term Assets $1.030M $256.0K
YoY Change 302.34% -44.83%
Inventory
Prepaid Expenses
Receivables $391.0K $147.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $25.22M $28.11M
YoY Change -10.27% -19.69%
LONG-TERM ASSETS
Property, Plant & Equipment $153.0K $201.0K
YoY Change -23.88% -17.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $153.0K $201.0K
YoY Change -23.88% -17.62%
TOTAL ASSETS
Total Short-Term Assets $25.22M $28.11M
Total Long-Term Assets $153.0K $201.0K
Total Assets $25.37M $28.31M
YoY Change -10.37% -19.67%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $364.0K $110.0K
YoY Change 230.91% -78.17%
Accrued Expenses $1.296M $1.075M
YoY Change 20.56% -16.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.660M $1.232M
YoY Change 34.74% -31.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $108.0K $162.0K
YoY Change -33.33% -22.49%
Total Long-Term Liabilities $108.0K $162.0K
YoY Change -33.33% -22.49%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.660M $1.232M
Total Long-Term Liabilities $108.0K $162.0K
Total Liabilities $767.0K $1.394M
YoY Change -44.98% 9.33%
SHAREHOLDERS EQUITY
Retained Earnings -$231.5M -$220.7M
YoY Change 4.87%
Common Stock $318.0K $309.0K
YoY Change 2.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $24.61M $27.79M
YoY Change
Total Liabilities & Shareholders Equity $25.37M $28.31M
YoY Change -10.37% -19.67%

Cashflow Statement

Concept 2024 Q1 2023 Q1
OPERATING ACTIVITIES
Net Income -$3.255M -$2.322M
YoY Change 40.18% -39.36%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.309M -$1.988M
YoY Change 16.15% 66.08%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $129.0K -$585.0K
YoY Change -122.05% -131.62%
Cash From Investing Activities $129.0K -$585.0K
YoY Change -122.05% -131.62%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.263M $3.000K
YoY Change 75333.33%
NET CHANGE
Cash From Operating Activities -2.309M -$1.988M
Cash From Investing Activities 129.0K -$585.0K
Cash From Financing Activities 2.263M $3.000K
Net Change In Cash 83.00K -$2.570M
YoY Change -103.23%
FREE CASH FLOW
Cash From Operating Activities -$2.309M -$1.988M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--10-31
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000715446
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-01-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-37492
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
ANIXA BIOSCIENCES, INC.
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-2622630
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
3150 Almaden Expressway
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 250
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
San Jose
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95118
CY2024Q1 dei City Area Code
CityAreaCode
(408)
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
708-9808
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $.01 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
ANIX
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
31899800 shares
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
998000 usd
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
915000 usd
CY2024Q1 us-gaap Short Term Investments
ShortTermInvestments
22800000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
22929000 usd
CY2024Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
391000 usd
CY2023Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
270000 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1030000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1242000 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
25219000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
25356000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
153000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
166000 usd
CY2024Q1 us-gaap Assets
Assets
25372000 usd
CY2023Q4 us-gaap Assets
Assets
25522000 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
364000 usd
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
206000 usd
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1242000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1770000 usd
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
54000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
52000 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1660000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2028000 usd
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
108000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
123000 usd
CY2024Q1 us-gaap Liabilities
Liabilities
1768000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
2151000 usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
100
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
100
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
19860 shares
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
19860 shares
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31754375 shares
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31754375 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
31145219 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
31145219 shares
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
318000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
311000 usd
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
255738000 usd
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
252222000 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-231451000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-228196000 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
24605000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
24337000 usd
CY2024Q1 us-gaap Minority Interest
MinorityInterest
-1001000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-966000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
23604000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
23371000 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25372000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25522000 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1349000 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1068000 usd
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2260000 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1488000 usd
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
3609000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
2556000 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3609000 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2556000 usd
CY2024Q1 us-gaap Interest Income Other
InterestIncomeOther
319000 usd
CY2023Q1 us-gaap Interest Income Other
InterestIncomeOther
202000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3290000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-2354000 usd
CY2024Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-35000 usd
CY2023Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-32000 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-3255000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2322000 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.10
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.10
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.08
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.08
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
31446 shares
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
31446 shares
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30921 shares
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30921 shares
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
23371000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1108000 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
56000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
96000 usd
CY2024Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
68000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2196000 usd
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
67000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3290000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
23604000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
28200000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
28200000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
957000 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
81000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
25000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-2354000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
26912000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
26912000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3290000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-2354000 usd
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1108000 usd
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
957000 usd
CY2024Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
56000 usd
CY2023Q1 us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
81000 usd
CY2024Q1 ANIX Common Stock Issued To Consultants
CommonStockIssuedToConsultants
96000 usd
CY2023Q1 ANIX Common Stock Issued To Consultants
CommonStockIssuedToConsultants
25000 usd
CY2024Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
13000 usd
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
11000 usd
CY2024Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
121000 usd
CY2023Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
100000 usd
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-212000 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-210000 usd
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
158000 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-155000 usd
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-528000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-651000 usd
CY2024Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-13000 usd
CY2023Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-12000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2309000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1988000 usd
CY2024Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
20020000 usd
CY2023Q1 us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
7835000 usd
CY2024Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
20149000 usd
CY2023Q1 us-gaap Proceeds From Sale Of Short Term Investments
ProceedsFromSaleOfShortTermInvestments
7250000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
129000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-585000 usd
CY2024Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2196000 usd
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
67000 usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3000 usd
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2263000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
83000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2570000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
915000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
12360000 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
998000 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
9790000 usd
CY2024Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2196000 usd
CY2024Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
555820 shares
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-966000 usd
CY2024Q1 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-35000 usd
CY2024Q1 us-gaap Minority Interest
MinorityInterest
-1001000 usd
CY2024Q1 ANIX Revenue Recognition Percentage
RevenueRecognitionPercentage
1 pure
CY2024Q1 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
23655000 usd
CY2023Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
23707000 usd
CY2024Q1 us-gaap Accrued Payroll Taxes Current And Noncurrent
AccruedPayrollTaxesCurrentAndNoncurrent
552000 usd
CY2023Q4 us-gaap Accrued Payroll Taxes Current And Noncurrent
AccruedPayrollTaxesCurrentAndNoncurrent
1114000 usd
CY2024Q1 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
626000 usd
CY2023Q4 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
626000 usd
CY2024Q1 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
64000 usd
CY2023Q4 us-gaap Other Accrued Liabilities Current And Noncurrent
OtherAccruedLiabilitiesCurrentAndNoncurrent
30000 usd
CY2024Q1 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1242000 usd
CY2023Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
1770000 usd
CY2024Q1 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0 usd
CY2023Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued
0 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
51000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
70000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
65000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
186000 usd
CY2024Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
24000 usd
CY2024Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
162000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3290000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-2354000 usd
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-3290000 usd
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-2354000 usd
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
3609000 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
2556000 usd
CY2024Q1 ANIX Noncash Sharebased Compensation
NoncashSharebasedCompensation
-1260000 usd
CY2023Q1 ANIX Noncash Sharebased Compensation
NoncashSharebasedCompensation
-1063000 usd
CY2024Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2349000 usd
CY2023Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1493000 usd
CY2024Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2349000 usd
CY2023Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1493000 usd
CY2024Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2349000 usd
CY2023Q1 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1493000 usd
CY2024Q1 us-gaap Assets
Assets
25372000 usd
CY2023Q4 us-gaap Assets
Assets
25522000 usd
CY2024Q1 us-gaap Assets
Assets
25372000 usd
CY2023Q4 us-gaap Assets
Assets
25522000 usd

Files In Submission

Name View Source Status
0001493152-24-009683-index-headers.html Edgar Link pending
0001493152-24-009683-index.html Edgar Link pending
0001493152-24-009683.txt Edgar Link pending
0001493152-24-009683-xbrl.zip Edgar Link pending
anix-20240131.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
anix-20240131_def.xml Edgar Link unprocessable
anix-20240131_lab.xml Edgar Link unprocessable
anix-20240131_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
anix-20240131_cal.xml Edgar Link unprocessable